

ORAL PRESENTATION

Open Access

Vaccine targeting HIF1A in triple negative breast cancer

Denise Cecil^{1*}, Daniel Herendeen¹, Meredith Slota¹, Yushe Dang¹, Megan O'Meara², Ekram Gad¹, Lauren Rastetter¹, Marlese Koehnlein¹, Mary L Disis¹

From Society for Immunotherapy of Cancer 29th Annual Meeting
National Harbor, MD, USA. 6-9 November 2014

The high rates of relapse in triple negative breast cancer (TNBC) are thought to be due to the presence of increased levels of cancer stem cells (CSC), which have been shown to be resistant to standard therapies. It has been demonstrated that hypoxia-inducible factor 1 (HIF1A) can induce the expression of numerous gene products associated with stem-ness and epithelial-mesenchymal transition in breast cancer cells and has been shown to be hyperactivated in TNBC. In this study, we aimed to target HIF1A with a therapeutic immune response through active immunization. HIF1A is a tumor-associated antigen. We have determined that both the magnitude and incidence of HIF1A-specific IgG is significantly elevated in TNBC compared to volunteer donors. We identified epitopes derived from HIF1A that selectively elicited IFN-gamma secretion with little to no IL-10 secretion in human peripheral blood mononuclear cells and T cell lines generated with these epitopes responded to recombinant HIF1A protein. Furthermore, these epitopes are highly homologous between mouse and man. To evaluate therapeutic efficacy, we immunized MMTV-neu (HER2⁺ model) and C3(1)Tag (TNBC model) mice with a plasmid-based vaccine containing an extended sequence of the identified epitopes. Tumor growth was inhibited over 80% ($p < 0.0001$) in the TNBC model; however, growth was inhibited only by 40% ($p < 0.01$) in the HER2⁺ model. We determined the majority of the tumor cells from the TNBC model expressed the mouse stem cell marker, Sca-1, whereas only a minority of the cells derived from the HER2⁺ model expressed the marker. Finally, we detected a 52% decrease in tumor Sca-1 expression after HIF1A-specific vaccination in the TNBC model ($p = 0.004$). Targeting HIF1A via active

immunization may be an effective way to prevent disease relapse in patients with TNBC.

Authors' details

¹University of Washington, Seattle, WA, United States. ²Seattle Genetics, Seattle, WA, United States.

Published: 6 November 2014

doi:10.1186/2051-1426-2-S3-O5

Cite this article as: Cecil et al.: Vaccine targeting HIF1A in triple negative breast cancer. *Journal for ImmunoTherapy of Cancer* 2014 **2** (Suppl 3):O5.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



¹University of Washington, Seattle, WA, United States
Full list of author information is available at the end of the article